phospho-CBL2 (Tyr700)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 4072R
英文名称phospho-CBL2 (Tyr700)
中文名称磷酸化原癌基因CBL2抗体
别 名phospho-C CBL (Tyr700); CBL2 (phospho-Tyr700); CBL2 (phospho-Y700); p-CBL2 (Tyr700); p-CBL2 (Y700); C CBL; Cas-Br-M (murine) ecotropic retroviral transforming sequence; Casitas B lineage lymphoma proto oncogene; CBL 2;E3 ubiquitin protein ligase CBL; Oncogene CBL2; Proto oncogene c CBL; RGD1561386; RING finger protein 55; RNF55v Signal transduction protein CBL; 4732447J05Rik; CBL_HUMAN.
规格价格100ul/1580元 购买 大包装/询价
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 **学 转录调节因子 b-**细胞
抗体来源Rabbit
克隆类型Polyclonal
phospho-CBL2 (Tyr700)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow, Horse,
产品应用ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量100kDa
细胞定位细胞浆 细胞膜
性 状Lyophilized or Liquid
浓 度1mg/ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human C CBL around the phosphorylation site of Tyr700:TE(p-Y)MT
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-CBL2 (Tyr700)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Mar 2012]
Function:
Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The Tyr-731 phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function.
Subunit:
Interacts (phosphorylated at Tyr-731) with PIK3R1. Associates with NCK via its SH3 domain. The phosphorylated C-terminus interacts with CD2AP via its second SH3 domain. Binds to UBE2L3. Interacts with adapters SLA, SLA2 and with the phosphorylated C-terminus of SH2B2. Interacts with EGFR, SYK and ZAP70 via the highly conserved Cbl-N region. Also interacts with SORBS1 and INPPL1/SHIP2. Interacts with phosphorylated LAT2. May interact with CBLB (By similarity). Interacts with ALK, AXL, BLK, FGR and FGFR2. Interacts with CSF1R, EPHB1, FLT1, KDR, PDGFRA and PDGFRB; regulates receptor degradation through ubiquitination. Interacts with HCK and LYN. Interacts with TEK/TIE2 (tyrosine phosphorylated).
Subcellular Location:
Cytoplasm. Cell membrane. Note=Colocalizes with FGFR2 in lipid rafts at the cell membrane.
Post-translational modifications:
Phosphorylated on tyrosine residues by ALK, EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues in response to FLT1 and KIT signaling. Phosphorylated on tyrosine residues by INSR and FGR. Phosphorylated on several tyrosine residues by constitutively activated FGFR3. Not phosphorylated at Tyr-731 by FGFR3. Phosphorylated on tyrosine residues by activated CSF1R, PDGFRA and PDGFRB. Phosphorylated on tyrosine residues by HCK.
Ubiquitinated, leading to its degradation via the proteasome.
DISEASE:
Defects in CBL are the cause of Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia (NSLL) [MIM:613563]. A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects.
Similarity:
Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
Contains 1 RING-type zinc finger.
Contains 1 UBA domain.
SWISS:
P22681
Gene ID:
867
phospho-CBL2 (Tyr700)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-CBL2 (Tyr700)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 MTOR 雷帕霉素靶蛋白抗体
合格 TIMM22 线粒体内膜转位同源蛋白22抗体
合格 TIMM50 线粒体内膜转位同源蛋白50抗体
合格 TIP49A TIP60相关蛋白54α抗体
合格 TIPIN TIMELESS相互作用蛋白抗体
合格 TM2D1 β淀粉样蛋白结合蛋白抗体
合格 TMCO3 跨膜和卷曲螺旋结构域蛋白3抗体
合格 TMEM109 跨膜蛋白109抗体
合格 PRDM5 PR结构域锌指蛋白5抗体
合格 PREX2 磷脂酰肌醇PREX2抗体
合格 PRKRIR 蛋白激酶PKR抑制蛋白PRKRIR抗体
合格 PPP2R2D 蛋白磷酸酶2调节亚基2D抗体
合格 CD171/L1CAM 神经细胞粘附分子配体1抗体
合格 PPP2R5A 蛋白磷酸酶2调节亚基5A抗体
合格 PPP2R5E 蛋白磷酸酶2调节亚基5E抗体
合格 合格 PPP3CC 蛋白磷酸酶3调节亚基C抗体
合格 PPP3R2 蛋白磷酸酶3调节亚基R2抗体
合格 PPP1R16B 蛋白磷酸酶1调节亚基抑制蛋白16B抗体
合格 合格 PABP2 多聚腺苷酸结合蛋白2抗体
合格 PACSIN2 胞浆磷蛋白PACSIN2抗体
合格 合格 RUNX2 核心结合因子α1/成骨特异性转录因子/Cbfα1抗体
合格 Intestinal alkaline phosphatase 肠道碱性磷酸酶抗体
合格 合格 Placental alkaline phosphatase 胎盘碱性磷酸酶抗体
合格 CARD12 凋亡加强结构域蛋白12抗体
合格 PIM3 丝氨酸/苏氨酸蛋白激酶PIM3抗体
合格 phospho-GFAP (Thr7) 磷酸化胶质纤维酸性蛋白抗体
合格 C19orf56 19号染色体开放阅读框56抗体
合格 HSV1 + HSV2 gD 单纯疱疹病毒糖蛋白D抗体
合格 合格 UGT1A7 尿苷二磷酸葡糖醛基转移酶1A7抗体
合格 PCNA 增殖细胞核抗原抗体
合格 LY6G6F **细胞抗原6重复位点蛋白G6F抗体
合格 合格 合格 phospho-CDKN1B (Ser10) 磷酸化P27抗体/周期素依赖激酶抑制剂
合格 合格 Phospho-NFKB1 (Ser373) 磷酸化细胞核因子p50/k基因结合核因子抗体
合格 Tyrosine Hydroxylase Tyrosine Hydroxylase
合格 合格 PCNA 增殖细胞核抗原抗体
合格 Tyrosine Hydroxylase 酪氨酸羟化酶抗体
合格 合格 GPR106 G蛋白偶联受体106抗体
合格 EGF 表皮生长因子抗体
合格 ACTG1 肌动蛋白γ1抗体